GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tempest Therapeutics Inc (NAS:TPST) » Definitions » Change In Prepaid Assets

Tempest Therapeutics (Tempest Therapeutics) Change In Prepaid Assets : $0.18 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Tempest Therapeutics Change In Prepaid Assets?

Tempest Therapeutics's Change In Prepaid Assets for the quarter that ended in Mar. 2024 was $-0.04 Mil. It means Tempest Therapeutics's Prepaid Assets declined by $0.04 Mil from Dec. 2023 to Mar. 2024 .

Tempest Therapeutics's Change In Prepaid Assets for the fiscal year that ended in Dec. 2023 was $0.19 Mil. It means Tempest Therapeutics's Prepaid Assets increased by $0.19 Mil from Dec. 2022 to Dec. 2023 .


Tempest Therapeutics Change In Prepaid Assets Historical Data

The historical data trend for Tempest Therapeutics's Change In Prepaid Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tempest Therapeutics Change In Prepaid Assets Chart

Tempest Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Change In Prepaid Assets
-0.37 -0.18 0.92 0.19

Tempest Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Prepaid Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 0.40 -0.22 0.04 -0.04

Tempest Therapeutics Change In Prepaid Assets Calculation

Change In Prepaid Assets is any increase or decrease between periods of the prepaid assets.

Change In Prepaid Assets for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tempest Therapeutics Change In Prepaid Assets Related Terms

Thank you for viewing the detailed overview of Tempest Therapeutics's Change In Prepaid Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Tempest Therapeutics (Tempest Therapeutics) Business Description

Traded in Other Exchanges
Address
2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005
Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.
Executives
Justin Trojanowski officer: Corporate Controller C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080
Nicholas Maestas officer: VP of Strategy and Finance 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 20005
Versant Venture Capital Vi, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iv, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Venture Capital Iv, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Iv, Llc 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Thomas Woiwode director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Vi Gp-gp, Llc 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Vi Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Vantage Ii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp-gp, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Thomas W. Dubensky director, officer: President C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Samuel Whiting officer: Chief Medical Officer C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080
Rock Springs Capital Llc 10 percent owner 650 SOUTH EXETER STREET, SUITE 1070, BALTIMORE MD 21202